New hope for kidney transplant patients: safer CMV prevention on the horizon?
NCT ID NCT06034925
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 28 times
Summary
This study tested whether a different medication, maribavir, is better tolerated and as effective as the standard drug valganciclovir for preventing CMV infection in 70 high-risk kidney transplant recipients. The goal was to see which drug causes fewer side effects like low white blood cell counts while still preventing CMV. Results will help doctors choose the best preventive treatment for these patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSPLANT COMPLICATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
Conditions
Explore the condition pages connected to this study.